What is the recommended oral antiviral treatment regimen for an adult with oral herpes (HSV‑1), including dosing for primary infection, recurrence, and suppressive therapy?

Oral Herpes Treatment Recommendations

For oral herpes (HSV-1) in adults, treat primary infection with acyclovir 400 mg orally 5 times daily for 7-10 days, recurrent episodes with acyclovir 400 mg three times daily for 5 days (started during prodrome or within 1 day of lesion onset), and suppressive therapy with acyclovir 400 mg twice daily for patients with ≥6 recurrences per year.

Primary (First Clinical Episode) Oral HSV Infection

The evidence for oral herpes treatment is primarily extrapolated from genital herpes guidelines, as the provided guidelines focus on genital disease. However, the treatment principles apply to orolabial HSV infections.

For moderate to severe primary oral HSV infection:

• Acyclovir 400 mg orally 5 times daily for 7-10 days until clinical resolution 1
• Alternative: Acyclovir 200 mg orally 5 times daily for 7-10 days 1
• For severe disease requiring hospitalization: Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days 1

For moderate to severe symptomatic gingivostomatitis:

• Start with acyclovir 5-10 mg/kg IV three times daily, then transition to oral therapy once lesions begin regressing 2
• Continue until lesions completely heal

For mild symptomatic gingivostomatitis:

• Acyclovir 20 mg/kg (maximum 400 mg/dose) orally three times daily for 5-10 days 2

The key is early initiation—systemic antiviral therapy is widely accepted as effective for primary herpetic gingivostomatitis 3.

Recurrent Episodes

Treatment efficacy depends critically on timing. When started during prodrome or within 1 day of lesion onset, patients experience meaningful benefit 4. However, most immunocompetent patients cannot achieve this early treatment window.

Recommended regimens for recurrent oral herpes:

• Acyclovir 400 mg orally three times daily for 5 days 4
• Alternative: Acyclovir 200 mg orally five times daily for 5 days 4
• Alternative: Acyclovir 800 mg orally twice daily for 5 days 4
• Valacyclovir 500-1000 mg orally twice daily for 3-5 days 5
• Valacyclovir 2 g orally twice daily for 1 day (single-day therapy) 4
• Famciclovir 1500 mg as a single dose 6

Important caveat: The 1993 CDC guidelines 1 stated that treatment is "not generally recommended" for recurrent episodes in immunocompetent patients because early treatment is seldom achieved. However, the 1998 guidelines 4 reversed this position, acknowledging that many patients benefit from episodic therapy when initiated early. More recent research 5, 3 confirms that systemic antivirals reduce lesion duration when applied early.

Topical therapy considerations:

• Acyclovir 5% cream may reduce lesion duration if applied very early 5, 3
• Topical therapy is substantially less effective than oral treatment 1
• Penciclovir 1% cream and docosanol are alternatives, though comparative efficacy data are limited 3

Suppressive Therapy

Indications: Patients with frequent recurrences (≥6 episodes per year) 1, 4

Recommended regimens:

• Acyclovir 400 mg orally twice daily 1, 4
• Alternative: Acyclovir 200 mg orally 3-5 times daily (titrate to lowest effective dose) 1
• Valacyclovir 500 mg orally twice daily 4
• Valacyclovir 500-2000 mg daily for prevention 5
• Famciclovir 250 mg orally twice daily 4

Key management points:

• Suppressive therapy reduces recurrence frequency by ≥75% 1, 4
• Safety documented for acyclovir up to 6 years, valacyclovir and famciclovir for 1 year 4
• After 1 year of continuous therapy, discontinue to reassess recurrence rate 1, 4
• Suppressive therapy does not eliminate asymptomatic viral shedding 1, 4
• Acyclovir-resistant strains may emerge but rarely cause treatment failure in immunocompetent patients 1

Prophylaxis for specific triggers:

• Sunscreen alone (SPF ≥15) effectively prevents UV-triggered recurrences 5
• Acyclovir 400 mg 2-3 times daily for UV exposure prophylaxis 5

Special Populations

Immunocompromised patients:

• Require more aggressive therapy with prolonged treatment courses 1
• Higher risk for acyclovir-resistant strains requiring alternative agents (foscarnet 40 mg/kg IV three times daily or 60 mg/kg twice daily) 2
• Prophylactic oral acyclovir reduces frequency and severity of recurrences, though optimal timing/duration varies 3

Severe disease with complications:

• IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days for disseminated infection, encephalitis, pneumonitis, or hepatitis 1

Comparative Efficacy

The network meta-analysis from the Cochrane review 7 found no clear superiority between acyclovir, valacyclovir, and famciclovir for suppressive therapy. Valacyclovir and famciclovir offer improved dosing convenience (twice daily vs. five times daily for acyclovir), which enhances adherence for prolonged treatment 4.

Single-dose or short-course regimens (valacyclovir 2g twice daily for 1 day, famciclovir 1500 mg single dose) improve adherence while maintaining efficacy 6, 8.

Common Pitfalls

• Starting treatment too late: Antiviral efficacy drops dramatically if not initiated during prodrome or within 24 hours of lesion onset
• Underdosing: Using topical therapy alone when systemic therapy is indicated
• Premature discontinuation: Stopping treatment before complete lesion resolution in primary infections
• Not considering suppressive therapy: Failing to offer suppression to patients with frequent recurrences who would benefit from improved quality of life